Dongcheng Pharmaceuticals Receives Approval for Clinical Trial of 177Lu-LNC1009
December 8, 2025
Source: drugdu
81
On December 7th, Dongcheng Pharmaceutical(002675) issued an announcement stating that its holding subsidiary, Lannacheng, received the drug clinical trial approval notice for 177Lu-LNC1009 injection issued by the National Medical Products Administration on December 5, 2025, and plans to conduct relevant clinical trials in the near future. This drug is a dual-target radiotherapy drug, mainly used for the treatment of patients with FAP-positive and integrin αvβ3-positive advanced malignant solid tumors.
The total investment in the research and development of 177Lu-LNC1009 injection is approximately RMB 13.58 million. Currently, there are no similar products on the market domestically or internationally, and no relevant sales data is available. The company emphasizes that the process from drug development to market launch is lengthy and involves uncertainties, reminding investors to be aware of the risks.
In the first three quarters of 2025, Dongcheng Pharmaceutical achieved revenue of 2.043 billion yuan and net profit attributable to the parent company of 149 million yuan.
https://finance.eastmoney.com/a/202512073584597690.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Huihe Medical Completes Hundreds of Millions-yuan Series D Financing Round with China Taiping Healthcare Fund as Lead Investor, Fueling Chinese Indigenous Medical Devices for Global Expansion December 30, 2025
- FDA Approved! Novel Anti-Cancer Bispecific Antibody to Initiate Phase I Clinical Trial December 30, 2025
- Transcenta Group-B and EirGenix Reach Biopharmaceutical Manufacturing Collaboration Agreement December 30, 2025
- China’s first imported PD-L1 subcutaneous formulation approved! Atezolizumab subcutaneous formulation receives NMPA approval for market launch December 30, 2025
- Boston Scientific has changed its leadership in its core business! December 30, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
